Adenosine analogue-type A3 receptor agonists having an N6 nitrogen
substituted by a group which is usually --CH.sub.2-CYCLE, where CYCLE is
a specified heteroaromatic group, particularly a pyrridyl or a bicyclic
group, for example benzoxazole. Preferred CYCLE moieties are substituted
in specified positions by, in particular, halo or methyl and, at another
position, a dialkylamine.
